Studies have found that the combined use of programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune checkpoint inhibitors significantly enhance the anti-tumor immune response of CD8+ T cells and inhibit regulatory T cell function in tumor treatment compared to their use alone [9–11]. This evidence concerns the gene CD8A and neoplasm.